TABLE 2.
SLCO1B1*5 (rs4149056) genotyping results in both DILI cohorts compared to POPRES community controls.
| Genotype | TT (%) | CT (%) | CC (%) | p-value | Odds ratio | 95% CI |
|---|---|---|---|---|---|---|
| Flucloxacillin cases (n = 149) | 115 (77.2) | 31 (20.8) | 3 (2.0) | 0.17 | 0.71 | 0.46–1.12 |
| Flucloxacillin cases positive for rs2395029 (tag SNP for HLA-B*57:01) (n = 125) | 95 (76) | 27 (21.6) | 3 (2.4) | 0.28 | 0.76 | 0.47–1.23 |
| Flucloxacillin cases with cholestatic or mixed phenotypes*(n = 136) | 104 (76.5) | 29 (21.3) | 3 (2.2) | 0.64 | 0.90 | 0.57–1.41 |
| Co-amoxicillin cases (n = 162) | 119 (73.4) | 40 (24.7) | 3 (1.9) | 0.58 | 0.87 | 0.56–1.33 |
| POPRES controls (n = 282) | 199 (70.6) | 74 (26.2) | 9 (3.2) |
*Cases with mixed phenotypes are those which show both cholestatic and hepatocellular clinical manifestations.